Efficient harvest of in Vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (Lymphocytapheresis)

Journal of Hematotherapy and Stem Cell Research

Volumn 6, Issue 3, 1997, Pages 253-260

  Masucci, Giuseppe ^a   Svensson, Anna ^a   Hansson, Mona ^a   Hansson, Johan ^a   Nakazawa, Tsutomu ^b   Salazar, Flavio ^b   Petersson, Max ^b   Kiessling, Rolf ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CELL SELECTION; CLINICAL ARTICLE; CYTOTOXICITY TEST; FEMALE; HUMAN; LEUKAPHERESIS; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030872524     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1997.6.253     Document Type: Article

References (36)

1. Rosenberg, S.A., Lotze, M.T., Muul, L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889, 1987.
2. Legha, S.S. Current therapy for malignant melanoma. Semin. Oncol. 16(Suppl), 1989.
3. Rosenberg, S., Yanelli, J.R., Yang, J.C., et al. Treatment of patients with melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159, 1994.
4. Atzpodien, J., Körfer, A., Franks, C.R., et al. Home therapy with recombinant interieukin-2 and interferon-α2b in advanced human malignancies. Lancet 335:1509, 1991.
5. Atzpodien, J. & Kirchner, H. The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies. Eur. J. Cancer 27(Suppl. 4):888, 1991.
6. Rosenberg, S.A., Lotze, M.T., Muul, L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485, 1985.
7. West, H.W., Tauer, K.W., Yannelli, J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316:898, 1987.
8. Atzpodien, J., Franks, C.R., Evers, P., et al. Low dose subcutaneous recombinant interleukin-2 in advanced human malignancy. A phase II study. Mol Biother. 2:18, 1990.
9. Wersäll, P. & Masucci, G. Simplified long-term large-scale production of highly active human LAK cells for therapy. Med. Oncol. Tumor Pharmacother. 7:257, 1990.
10. Parmiani, G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today 11:113, 1990.
11. Crowely, N.J., Slingluff, C.L., Darrow, T.L., et al. Generation of human autologous melanoma-specific cytotoxic T cells using HLA-A2 matched allogeneic melanomas. Cancer Res. 50:492, 1990.
12. Parmiani, G., Anichini, A. & Fossati, G. Cellular immune response against autologous human malignant melanomas: Are in vitro studies providing a framework for a more effective immunotherapy? J. Natl. Cancer Inst. 82:361, 1990.
13. Wersäll, P., Hising, C., Masucci, G., et al. Long-term culture of cytotoxic tumor associated lymphocytes from ascites of ovarian carcinoma patients. Cancer Journal 3:321, 1990.
14. Wersäll, P., Masucci, G., Nielsen, J., et al. TNF-alpha and leukocyte alpha-IFN enhance IL-2-activated killer cell activity against cells in the absence or presence of monoclonal antibodies. Cancer Journal 3:147, 1990.
15. Strauss, G.R., Ciavarella, D., Gilcher R.O., et al. An overview of current management. Special issue: Clinical applications of therapeutic hemapheresis. J. Clin. Apheresis 8:189, 1993.
16. Pross, H.F., Baines, M.G. & Rubin, P. Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J. Clin. Immunol. 1:51, 1981.
17. Thompson, J.A., Lee, D.J., Cox, W.W., et al. Recombinant interleukin-2 (IL-2) toxicity, pharmacokinetics and immunomodulatory effects in a phase I trial. Cancer Res. 47:4202, 1987.
18. Herberman, R.B., Hiserodt, J., Vujanovic, N., et al. Lymphokine activated killer cell activity. Characteristic of effector cells and their progenitors in blood and spleen. Immunol. Today 8:178, 1987.
19. Topalian, S.L., Muul, L., Solomon, D., et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127, 1987.
20. 1-integrins on melanoma cell clones regulate the interaction with autologous cytolytic T cell clones. J. Immunother. 12:183, 1992.
21. Rivoltini, L., Kawakami, Y., Sakaguchi, K., et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257, 1995.
22. Atzopodien, J., Kirchner, H., de Mulder, P., et al. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: Results of a multicenter phase II Study. Cancer Biother. 8:289, 1993.
23. Sanders, M.E., Makgoba, M. & Shaw, S. Human naive and memory T cells: Reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol. Today 9:195, 1988.
24. Lanier, L., Testi, R., Bindi, J., et al. Identity of Leu-19 (CD56) leucocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 169:2233, 1989.
25. Converse, P., Ottenhoff, T., Saba, W.T., et al. Intradermal recombinant interleukin-2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Scand. J. Immunol. 32:83, 1990.
26. Matsuda, M., Petersson, M., Lenkei, R., et al. Alteration in the signal-transducing molecules of the T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int. J. Cancer 61:765, 1995.
27. Zea, A.H., Curti, B.D., Longo, D.L., et al. Alteration in T-cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1:1327, 1995.
28. Rosenberg, S., Lotze, M., Yang, J., et al. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622, 1993.
29. Keilholz, U., Scheibenbogen, C., Brado, M., et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine activated killer (LAK) cells for liver metastases. Eur. J. Cancer 30:103, 1994.
30. Negrier, S., Mercatello, A., Bret, M., et al. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma. J. Immunother. 17:62, 1995.
31. Murray-Law, T., Motzer, R., Mazumdar, M., et al. Phase II randomized trial of interleukin 2 with or without lymphokine activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824, 1995.
32. van Lunzen, J., Schmitz, J., Dengler, K., et al. Investigation on autologous T-cells for adoptive immunotherapy of AIDS. Adv. Exp. Med. Biol. 374:57, 1995.
33. Holladay, F., Heitz-Turner, T., Bayer, W., et al. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J. Neurooncol. 27:179, 1996.
34. Wersäl, J.P., Masucci, G., Hjelm, A.-L., et al. Low dose cyclophosphamide, alpha-interferon and continuous infusion of interleukin-2 in advanced renal cell carcinoma. Med. Oncol. Tumor Pharmacother. 10:103, 1993.
35. Huberman, M., Mittelman, A., Fallon, B., et al. Preliminary observations from a phase I study of recombinant human interleukin-2 (IL-2) and Roferon-A (recombinant human alpha-IFN) in patients with malignant B cell disease, renal and colorectal cancer, and melanoma. Proc. ASCO 7:169, 1988.
36. Bindon, C., Czerniecki, M., Ruell, P., et al. Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br. J. Cancer 47:123, 1983.